Fig. 4. Improvement of competitive inhibition activity by divalent peptide3A5.
A The binding capacity was measured at the indicated concentration using an ELISA-based assay. Similar results were obtained in three independent experiments. B SW480 cells were pretreated with 2.5 µM of divalent peptide3A5, and then stimulated with human S100A8 recombinant protein. After 30 min, cell lysates were subjected to western blotting using the indicated antibody. The divalent peptide#3 or peptide3A5 reduced the expression of S100A8-mediated IL-8 (C) and VEGF (D) induction. Total RNAs from SW480 cells with/without treatment of the peptide candidates were extracted and qPCR analysis was performed using relevant primer sets and SYBR green. Relative expression levels were compared. Peptide #3 suppresses S100A8-mediated IL-8(E) and VEGF (F) secretion in SW480 cells. Data are shown as mean ± SD. *P < 0.05 compared with treatment of S100A8.